COVID-19 Pandemic Drives Innovative Need For More Telemedicine And Remote Control Devices To Support Strained Medical Staff Who Need Greater Ability To Treat More Patients; Electromedical Technologies, Inc.’s (OTCQB: EMED) Devices Offer Relief For Patients With Chronic And Acute Pain


Hospital medical staffs are so overwhelmed by the newest spike in the COVID-19 pandemic, they say they will not have time for RNs (registered nurses) and even doctor’s advocates to inject masses of people with the newest vaccines. In this harried world, it is no wonder that physicians and technicians are seeking more telemedicine devices and products like Electromedical Technologies, Inc.’s (OTCQB: EMED) FDA cleared and non-invasive line of WellnessPro Plus™ products.

The chronic pain treatment market has drawn intense interest from media companies. features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT),  Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM).  GlaxoSmithKline (NYSE: GSK),  Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY),  Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).

COVID-19 Pandemic Drives Innovative Need For More Telemedicine And Remote Control Devices To Support Strained Medical Staff And Offer Ability To Treat More Patients;  Electromedical Technologies, Inc.’s (OTCQB: EMED) FDA cleared WellnessPro Plus™ Devices Offer Relief For Patients With Chronic And Acute Pain

As medical facilities try to cope with with the latest national spike in COVID-19 cases, Electromedical Technologies, Inc. (OTCQB: EMED) focuses on how to relieve chronic and acute pain with non-invasive devices which do have addictive pain killer drugs which may have the side effect of addiction to opioids. It saves overworked medical staffs from dealing with more complications from acute pain.

The WellnessPlus POD Portal For Remote Realtime Monitoring Of Treatment

Electromedical Technologies, Inc. (OTCQB: EMED) plays an important role in relieving pain in patients while offering a non-invasive solution via devices which do not incur more opioid addiction. In the future, the company plans to offer physicians, providers and trained technicians the smaller and feature-intensive WellnessPlus POD.

A smaller and less costly device, the POD model offers staff a special feature: a portal that enables supervising staff the ability to monitor in real time how a patient is receiving pain relief from the device. In a time of home-bound pandemic suffering patients, this is an important new feature. COVID-19 Pandemic Drives Innovative Need For More Telemedicine And Remote Control Devices To Support Strained Medical Staff And Offer  Ability To Treat More Patients;  Electromedical Technologies, Inc.’s (OTCQB: EMED) Devices Offer Relief For Patients With Chronic And Acute Pain.

Anticipating More Medical Practitioners And Distributors, EMED Invests In More Year-End Inventory

Already, Electromedical Technologies, Inc. (OTCQB: EMED) Has Built More WellnessPro Plus™ device inventory for an anticipated accelerated demand in 2021 for the product.  As an alternative to opioid-addicting pharmaceuticals, the device solves acute and chronic pain for patients.


Goldman Small Cap Research Report Projects EMED Will Reach $17 Million By 2022

A new Goldman Small Cap Research report projects EMED conservatively to reach $17 million in volume by 2022, and perhaps as high as $22 million with unit sales of its devices that year reaching 80,000 or 90,000 units. Goldman Small Cap Research projected EMED’s FDA cleared WellnessPro Plus device will exponentially grow in sales. COVID-19 Pandemic Drives Innovative Need For More Telemedicine And Remote Control Devices To Support Strained Medical Staff And Ability To Treat More Patients;  Electromedical Technologies, Inc.’s (OTCQB: EMED) Devices Offer Relief For Patients With Chronic And Acute Pain.

The analysis is especially bullish about the sales of the to-be-introduced in late 2021 after an anticipated FDA clearance of the WellnessPlus POD, which features a remote monitoring portal. The telemedicine-like remote portal will enable physicians and technicians to monitor in real time a remote view of therapy effectiveness — a trend as medical facilities are stressed due to COVID-19. The FDA has just issued emergency use authorizations for remote devices.

Remote Control Treatment Monitoring Trending In Medical Field

Certain remote or patient-wearing monitoring devices may enable physicians and caretakers to operate a medical device from a non co-located space with the patient. The strain of COVID-19 requires medical innovation and remote monitoring. Electromedical Technologies, Inc.’s (OTCQB: EMED) WellnessPlus POD with remote monitoring portal could be a key device.

Telemedicine Devices In Demand During Spike In COVID-19 Patients

In medical fields ranging from treatment of health and wellness and mental health, the use of remote monitoring devices enables medical facilities to provide treatments for patients and offer real time monitoring by medical providers. Remote Control  Monitoring For Medical Devices Trending I COVID-19 For Non-Invasive Treatment; Electromedical Technologies, Inc. (OTCQB: EMED) Leads As EMED’s WellnessPlus POD With Remote Monitoring Portal Will Provide Relief From Chronic And Acute Pain.

Projected Volume For EMED In 2022 Could Be $17-$22 Million: Goldman Report

The Goldman report projects that Electromedical Technologies, Inc. (OTCQB: EMED) could sell up to 80,000-90,000 units in 2022 with a premium portal feature that could provide remote monitoring of patient treatment and drive 2022 volume as high as $22 million. Goldman Small Cap Research last week set a $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED), in an Opportunity Research report.

The investment analysis projects that the medical device company will reach a volume of  $17+ Million in FY2022 and projects EMED will sell some 80,000-90,000 devices in 2022. The performance could be even greater. Medical institutions are looking to alternative therapies to relieve chronic and acute pain that do not contain prescription drugs, which have the side effect of addiction to opioids.

Remote Monitoring Portal Feature In POD Model Is Seen Driving Sales

The company has a combination purchase down payment/subscription payment revenue model which provides recurring revenue for sales of its devices. The upbeat forecast by Goldman SmallCap Research is largely based on prior sales of the FDA cleared Wellness Pro Plus.  Analyst Rob Goldman wrote that he was especially impressed with its telemedicine-like portal feature that permits physicians or technicians to monitor in real time and from a remote location how the wearable POD therapy is delivering relief from acute and chronic pain.

EMED Offers Devices Which Are Alternative To Opioid Addicting Pain Killer Drugs

Electromedical Technologies, Inc. (OTCQB: EMED has successfully marketed its non-invasive FDA-cleared WellnessPro Plus™ as an alternative treatment to opioid pain killer pharmaceuticals which can be addictive.

Inventory Build Up As  Electromedical Technologies, Inc. (OTCQB: EMED) Anticipates More Demand In 2021

For 2021, Matthew Wolfson, CEO, believes that patients who have experienced chronic pain relief from the bioelectronics and electro-modulation delivered by the Wellness Pro Plus devices warrant the investment in the year-end inventory build-up. In anticipation of a rush for the product in early 2021, the company has invested $4.2 Million as it has built and paid for a 1,200+ unit inventory in preparation for attracting hundreds more medical practitioners and distributors in 2021.

The WellnessPlus Pod Seen Debuting In Late 2021, After Anticipated FDA Clearance

Electromedical Technologies, Inc. (OTCQB: EMED) will debut in late 2021 the WellnessPlus POD, a smaller, professional, less costly device that features a special  portal for telemedicine-like real time monitoring by physicians. The WellnessPro POD links doctors/technicians and patients with that feature and is less costly, smaller, portable and offers a remote POD portal. The device also provides a unique financial sales structure for the Company, combining a down payment purchase with a recurring monthly subscription services fee.

Source: Stock Market Press

Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.

Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.


Stock Market Press
110 Wall St.
New York, NY 10005 Safe Harbor Statement:

Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

See Stock Market Press disclaimer: SOURCE: Stock Market Press